Cargando…

Antipsychotic treatment and cognitive function in patients with schizophrenia

INTRODUCTION: It is known that cognitive impairment is one of the main symptoms of schizophrenia, which determines the functional outcome. The question of the effect of antipsychotics on the cognitive functions of these patients is still unresolved. Cognitive impairment while taking antipsychotics i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tumova, M. A., Stepanova, A. A., Yanushko, M. G., Kotsyubinsky, A. P., Ivanov, M. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596312/ http://dx.doi.org/10.1192/j.eurpsy.2023.328

Ejemplares similares

Dynamics of contrast-frequency characteristics of the visual system in patients with schizophrenia
por: Tumova, M. A., et al.
Publicado: (2023)

Interrelation of visual and olfactory impairments in schizophrenia
por: Tumova, M., et al.
Publicado: (2021)

Characterization of “Responder” in patients with Treatment-Resistant Schizophrenia (TRS) treated with a new antipsychotic added to their current antipsychotic monotherapy
por: Anand, R., et al.
Publicado: (2023)

PM441. Long term atypical antipsychotic treatment improves cognitive performance in schizophrenia but not surpassing conventional antipsychotic drugs effects.
por: Vera, Gabriel Selva, et al.
Publicado: (2016)

Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder
por: Lähteenvuo, M., et al.
Publicado: (2021)

Schizophrenia long-acting antipsychotics initiation index (SLAAII)
por: Ifteni, P., et al.
Publicado: (2021)

Antipsychotics and mood stabilizers on risk for hepatic failure in people with schizophrenia and bipolar disorder
por: Tascón Guerra, M.F., et al.
Publicado: (2022)

The combination of long-acting injectable antipsychotics, a new key in resistant schizophrenia
por: Tascón Guerra, M.F., et al.
Publicado: (2022)

PM393. Antipsychotic polypharmacy patterns and antipsychotic psychiatric medication adherence in patients with schizophrenia
por: Joe, Soohyun, et al.
Publicado: (2016)

Swithching Antipsychotic Medications in People with Schizophrenia: A 4-Year Naturalistic Study
por: Ceres, R., et al.
Publicado: (2023)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

The effect of long-acting injectable antipsychotics on QRISK3 in patients with bipolar disorder and schizophrenia
por: Erbasan, V., et al.
Publicado: (2023)

Treatment of Cognitive Impairment in Schizophrenia
por: Vita, A.
Publicado: (2022)

F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Foussias, George, et al.
Publicado: (2018)

Influence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia
por: Rehse, Michael, et al.
Publicado: (2016)

Differential effects of specific antipsychotic drugs on metabolic markers and diabetes: A register-based study on 4,909 patients with schizophrenia
por: Sørensen, M. A., et al.
Publicado: (2023)

Which antipsychotics can we use for obsessive-compulsive symptoms in schizophrenia?
por: Aissa, A., et al.
Publicado: (2021)

Evenamide, as an add-on to antipsychotics, benefits patients with treatment resistant schizophrenia: 6-month interim results from the first 100 patients in an ongoing international randomized study
por: Anand, R., et al.
Publicado: (2023)

Prediction of quality of life in schizophrenia using machine learning models on data from clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial
por: Beaudoin, M., et al.
Publicado: (2021)

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

The risk of developing diabetes during antipsychotic drug treatment: A nationwide study among 31,856 patients with schizophrenia
por: Marker Madsen, N., et al.
Publicado: (2023)

Effectiveness of oral versus long-acting antipsychotic treatment early-phase schizophrenia patients: an open-label randomized trial
por: Winter, I., et al.
Publicado: (2022)

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
por: Yu, Zhi-min, et al.
Publicado: (2019)

Cariprazine as a useful treatment for patients with schizophrenia and antipsychotic-induced extrapyramidal symptoms: a case report and literature review
por: Llach, C., et al.
Publicado: (2022)

Recognition and Assessment of Cognitive Impairment in Schizophrenia
por: Mucci, A., et al.
Publicado: (2022)

S235. MAINTENANCE TREATMENT WITH ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENIA – SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2018)

S250. RELATION BETWEEN PSYCHOPATHOLOGY AND QUALITY OF LIFE IN SCHIZOPHRENIA PATIENTS BEFORE AND AFTER FIRST ANTIPSYCHOTIC TREATMENT
por: Andersen, Gitte, et al.
Publicado: (2018)

EPA guidance on treatment of cognitive impairment in schizophrenia
por: Vita, A.
Publicado: (2023)

The heterogeneity of antipsychotic response in the treatment of schizophrenia
por: Case, M., et al.
Publicado: (2011)

T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION
por: Kanji, Sarah, et al.
Publicado: (2018)

Characterising the evolution of antipsychotic polypharmacy and clozapine prescribing patterns in schizophrenia patients during psychiatric hospitalisations
por: Lagreula, J., et al.
Publicado: (2022)

Can Antipsychotics Improve Social Cognition in Patients with Schizophrenia?
por: Kucharska-Pietura, Katarzyna, et al.
Publicado: (2013)

Late-onset schizophrenia patients with social phobia receive higher doses of antipsychotics compared patients without social phobia: results of an observational study
por: Pochueva, V., et al.
Publicado: (2022)

A polydiagnostic approach to cognitive deficits in schizophrenia
por: Sánchez-Torres, A., et al.
Publicado: (2021)

Comparison of VR-Assisted Therapy to Cognitive-Behavioral Therapy in the treatment of verbal hallucinations in patient with treatment-resistant schizophrenia
por: Beaudoin, M., et al.
Publicado: (2023)

Correlates of late-onset antipsychotic treatment resistance
por: Fonseca De Freitas, D., et al.
Publicado: (2022)

Preliminary results of a network meta-analysis on the efficacy of long-acting injectable antipsychotics in schizophrenia
por: Medrano, R., et al.
Publicado: (2021)

Sexual disfunction in adolescents with antipsychotics. evaluation and suitability of the treatment
por: Sánchez, S. Pérez, et al.
Publicado: (2021)

Analysis of Oral versus Long-acting Injectable Antipsychotics in the Maintenance of Schizophrenia
por: Vasiliu, O.
Publicado: (2022)

Cognitive impairment in treatment-refractory schizophrenia and type i diabetes. A case
por: Rodriguez, L. Soldado, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m34g8djatf41k1db3dfvil4h81